AMFR and breast cancer: Compared with the PAM50 risk-of-recurrence (ROR) score (ROR/Prosigna) (66), the gp78 gene modules derived from the differential gene expression pattern of patients with breast cancer, stratified using the median cutoff for gp78 expression in the total cohort (labeled as Medcut_All), shows significantly higher scoring in patients with recurrent disease.